Table 2 Confirmation assays of plasma proteins in diabetes and their potential to discriminate lower limb sclerosis from controls (pg/ml).

From: Siglec-5 is a novel marker of critical limb ischemia in patients with diabetes

Proteins

protein array cohort†

confirmation cohort

CLI (n = 4)

Non-CLI (n = 4)

CLI (n = 59)

Non-CLI (n = 108)

BMP-4

497.34 ± 26.24#

385.74 ± 20.66

558.57 ± 34.20#

437.14 (330.11–544.50)‡

IGFBP-6

209.06 ± 21.49#

99.93 ± 17.95

195.62 ± 19.59#

124.14 (88.49–167.22)‡

NCAM-1

(182.92 ± 11.42)*10−3#

(277.58 ± 18.64)*10−3

(264.20 ± 8.25)*10−3

(264.40 ± 7.11)*10−3

MSP-alpha

57.34 ± 6.99#

31.60 ± 3.14

59.30 ± 3.21

58.79 ± 2.13

Siglec-5

(258.76 ± 37.21)*103#

(45.66 ± 6.00)*103

(193.62 (158.08–196.32))*103###

(73.84 ± 4.76)*103‡

Axl

14.64 ± 1.48#

26.71 ± 1.64

23.33 ± 1.36

21.37 (13.74–29.02)‡

Decorin

(1.90 ± 0.30)*103#

(3.52 ± 0.16)*103

(3.75 ± 0.18)*103##

(3.14 ± 0.12)*103

Trappin-2

33.42 ± 2.78#

14.08 ± 2.49

23.22 (13.23–50.34)###

13.22 (9.43–19.02)‡

EpCAM

10.23 ± 0.23#

5.00 ± 1.25

7.30 ± 0.68

6.50 (1.38–10.88)‡

TIMP-4

(4.19 ± 0.30)*103#

(2.08 ± 0.21)*103

(3.94 ± 0.41)*103###

(2.18 ± 0.22)*103

CDH5

(40.26 ± 1.77)*103#

(29.47 ± 1.59)*103

(37.92 ± 1.23)*103###

(32.92 ± 0.56)*103

  1. Data is shown as mean ± SEM, median (interquartile range) of subjects in each group. Differences between the groups in the protein array cohort were analyzed using †) Fisher-Pitman Permutation test, however, the confirmation cohort was analyzed using ‡) Mann-Whitney U-test, all the others were analyzed using t-tests. # p < 0.05; ## p < 0.01; ### p < 0.001.
Back to article page